Volume 8, Number 11—November 2002
THEME ISSUE
Tuberculosis Genotyping
Tuberculosis Genotyping Network, United States
Molecular Epidemiology of Multidrug-Resistant Tuberculosis, New York City, 1995–1997
Sonal S. Munsiff*†
, Trina Bassoff*, Beth Nivin*, Jiehui Li*, Anu Sharma*, Pablo Bifani‡, Barun Mathema‡, Jeffrey Driscoll§, and Barry N. Kreiswirth‡
, Trina Bassoff*, Beth Nivin*, Jiehui Li*, Anu Sharma*, Pablo Bifani‡, Barun Mathema‡, Jeffrey Driscoll§, and Barry N. Kreiswirth‡
Table 3
Risk factors associated with clustering of multidrug-resistant tuberculosis cases, New York City, 1995–1997 (n=234)
| Characteristic | Clustered (n=153) No. (%) | Nonclustered (n-81) No. (%) | Crude OR | 95% CI | |
|---|---|---|---|---|---|
| Median age in yr (range) | 41 (5–85) | 42 (22–77) | 0.99 | 0.98, 1.02 | |
| Male sex | 93 (60.8) | 49 (60.5) | 1.01 | 0.58, 1.76 | |
| U.S.-born | 120 (79.0) | 42 (51.9) | 3.48 | 1.94, 6.25 | |
| Median years of residence in United Statesb | 12 (0–47) | 6.5 (0–24) | 1.09 | 1.02, 1.16 | |
| HIV serostatus | |||||
| Positive | 96 (62.8) | 29 (35.8) | 2.81 | 1.52, 5.22 | |
| Negative | 40 (26.1) | 34 (42.0) | 1.00 | ||
| Unknown | 17 (11.1) | 18 (22.2) | 0.80 | 0.36, 1.80 | |
| Race/ethnicity | |||||
| Asian | 6 (3.9) | 16 (19.8) | 0.18 | 0.06, 0.53 | |
| Hispanic | 49 (32.0) | 24 (29.6) | 1.00 | ||
| Black non-Hispanic | 72 (47.1) | 31 (38.3) | 1.14 | 0.60, 2.17 | |
| White non-Hispanic | 26 (17.0) | 10 (12.4) | 1.27 | 0.53, 3.06 | |
| Health-care worker | 12 (7.8) | 2 (2.5) | 3.36 | 0.73, 15.40 | |
| Homeless | 22 (14.4) | 5 (6.2) | 2.55 | 0.92, 7.02 | |
| Injection drug usec | 24 (15.7) | 8 (9.9) | 1.70 | 0.73, 3.97 | |
| Prior treatment history | 10 (6.5) | 12 (14.8) | 0.40 | 0.17, 0.98 | |
| Having epidemiologic linkd | |||||
| Nosocomial | 7 (4.6) | 0 (0) | 2.97 | 1.02, 9.26 | |
| Community | 18 (11.8) | 5 (11.1) | |||
| No link | 128 (83.7) | 76 (88.9) | 1.00 | ||
| Year of diagnosis | |||||
| 1995 | 69 (45.1) | 32 (39.5) | 1.00 | ||
| 1996 | 54 (35.3) | 27 (33.3) | 0.93 | 0.47, 1.81 | |
| 1997 | 30 (19.6) | 22 (27.2) | 0.63 | 0.30, 1.34 | |
aOR, odds ratio; CI, confidence interval.
bExcludes non-U.S.-born patients.
cInjection drug use within 12 months before diagnosis.
dCompared epidemiologic link with no epidemiologic link
Page created: July 19, 2010
Page updated: July 19, 2010
Page reviewed: July 19, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.